{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Giddey AD"],"funding":["National Research Foundation"],"pubmed_abstract":["Despite the availability of effective drug treatment, <i>Mycobacterium tuberculosis</i> (Mtb), the causative agent of TB disease, kills ~1. 5 million people annually, and the rising prevalence of drug resistance increasingly threatens to worsen this plight. We previously showed that sublethal exposure to the frontline anti-TB drug, rifampicin, resulted in substantial adaptive remodeling of the proteome of the model organism, <i>Mycobacterium smegmatis</i>, in the drug-sensitive mc<sup>2</sup>155 strain [wild type (WT)]. In this study, we investigate whether these responses are conserved in an engineered, isogenic mutant harboring the clinically relevant S531L rifampicin resistance-conferring mutation (SL) and distinguish the responses that are specific to RNA polymerase β subunit- (RpoB-) "],"journal":["Frontiers in medicine"],"pagination":["723667"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8525676"],"repository":["biostudies-literature"],"pubmed_title":["Cell Wall Proteomics Reveal Phenotypic Adaption of Drug-Resistant <i>Mycobacterium smegmatis</i> to Subinhibitory Rifampicin Exposure."],"pmcid":["PMC8525676"],"pubmed_authors":["Soares NC","Ganief TA","Blackburn JM","Ganief N","Koch A","Giddey AD","Warner DF"],"additional_accession":[]},"is_claimable":false,"name":"Cell Wall Proteomics Reveal Phenotypic Adaption of Drug-Resistant <i>Mycobacterium smegmatis</i> to Subinhibitory Rifampicin Exposure.","description":"Despite the availability of effective drug treatment, <i>Mycobacterium tuberculosis</i> (Mtb), the causative agent of TB disease, kills ~1. 5 million people annually, and the rising prevalence of drug resistance increasingly threatens to worsen this plight. We previously showed that sublethal exposure to the frontline anti-TB drug, rifampicin, resulted in substantial adaptive remodeling of the proteome of the model organism, <i>Mycobacterium smegmatis</i>, in the drug-sensitive mc<sup>2</sup>155 strain [wild type (WT)]. In this study, we investigate whether these responses are conserved in an engineered, isogenic mutant harboring the clinically relevant S531L rifampicin resistance-conferring mutation (SL) and distinguish the responses that are specific to RNA polymerase β subunit- (RpoB-) ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-08T02:16:04.866Z","creation":"2024-11-15T17:46:52.582Z"},"accession":"S-EPMC8525676","cross_references":{"pubmed":["34676224"],"doi":["10.3389/fmed.2021.723667"]}}